These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31243239)

  • 1. Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
    Murakami S; Nagano T; Nakata K; Onishi A; Umezawa K; Katsurada N; Yamamoto M; Tachihara M; Kobayashi K; Nishimura Y
    Intern Med; 2019 Oct; 58(19):2839-2843. PubMed ID: 31243239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer.
    Okawa S; Kayatani H; Fujiwara K; Ozeki T; Takada K; Iwamoto Y; Minami D; Sato K; Shibayama T
    Intern Med; 2019; 58(5):699-702. PubMed ID: 30828042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
    Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
    J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
    Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
    Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
    Yonenobu Y; Ishijima M; Toyooka K; Fujimura H
    Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
    Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
    J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
    Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
    J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
    Hirabae A; Ichihara E; Sunami R; Ota M; Iwamoto Y; Maeda Y; Kiura K
    Acta Med Okayama; 2020 Oct; 74(5):423-425. PubMed ID: 33106698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
    Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
    In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
    Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
    Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
    Basnet S; Dhital R; Tharu B
    Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.